What Melinta Therapeutics does

Melinta Therapeutics, LLC is a commercial-stage biopharmaceutical company that develops, markets, and distributes anti-infective therapeutics targeting acute and life-threatening infections. The company's portfolio comprises seven FDA-approved products: REZZAYO (rezafungin for injection), a once-weekly echinocandin antifungal for candidemia and invasive candidiasis; VABOMERE (meropenem and vaborbactam), a carbapenem plus beta-lactamase inhibitor combination for carbapenem-resistant Enterobacteriaceae; BAXDELA (delafloxacin), a fluoroquinolone for acute bacterial skin and skin structure infections; KIMYRSA and ORBACTIV (oritavancin), single-dose lipoglycopeptide antibiotics for ABSSSI; MINOCIN (minocycline) for Injection, an intravenous tetracycline; and TOPROL-XL (metoprolol succinate), a cardiovascular beta-blocker. The company also held U.S. commercialization rights to the investigational beta-lactam/BLI combination cefepime-taniborbactam licensed from Venatorx Pharmaceuticals.

The business sells primarily into U.S. hospitals, hospital systems, specialty pharmacies, and home infusion providers through an enterprise field sales motion and formulary adoption. International distribution is executed via channel partnerships with Eurofarma, Hikma, Menarini, and Xediton in select regions. Development-stage funding includes a multi-year BARDA partnership that delivered an initial $20.5 million award in July 2023 with potential expansion to $141.9 million for supplemental antibiotic indications, including pediatric and biothreat applications. Under Deerfield Management ownership from 2020, the company reportedly delivered 85% cumulative revenue growth, positive cash flow, and sustainable profitability.

In August 2025, CorMedix Inc. acquired Melinta for $300 million ($260M cash plus $40M CorMedix equity), with up to $25 million in FDA milestone payments tied to REZZAYO prophylaxis approval and tiered royalties. The transaction closed in September 2025, transforming Melinta into a wholly-owned subsidiary of CorMedix. The company's headquarters were located in Parsippany, New Jersey with a second office in Lake Forest, Illinois.

Name

Melinta Therapeutics

Legal name

Melinta Therapeutics, LLC

Website

https://melinta.com

Company type

Private

Founded year

2017

Operating status

Acquired

Headcount range

101–250 employees

Short description

Melinta Therapeutics is a commercial-stage biopharmaceutical company that markets a portfolio of seven FDA-approved anti-infective drugs, including REZZAYO, VABOMERE, BAXDELA, KIMYRSA, ORBACTIV, MINOCIN, and TOPROL-XL, sold primarily to U.S. hospitals and acute care settings. Following its August 2025 acquisition by CorMedix for $300 million, it operates as a wholly-owned subsidiary.

Ownership category

akta.pro rank

Headquarters

HQ city

New Haven

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from sales of commercial-stage anti-infective products including REZZAYO, MINOCIN, VABOMERE, KIMYRSA, ORBACTIV, BAXDELA, and TOPROL-XL. Products sold to hospitals, healthcare providers, and through specialty pharmacies.
2. BARDA Funding: Government funding from Biomedical Advanced Research and Development Authority (BARDA) to advance FDA-approved antibiotic candidates through supplemental new drug applications, with initial funding of $20.5 million and potential up to $141.9 million.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Melinta Therapeutics develops, manufactures, and commercializes a portfolio of seven FDA-approved anti-infective pharmaceutical products, including antibiotics (BAXDELA, KIMYRSA, ORBACTIV, MINOCIN, VABOMERE), a once-weekly echinocandin antifungal (REZZAYO), and a cardiovascular beta-blocker (TOPROL-XL), plus the investigational cefepime-taniborbactam licensed from Venatorx. Products are sold to hospitals, healthcare providers, and specialty/home infusion channels in the US and through international distribution partners, targeting acute, life-threatening bacterial and fungal infections including drug-resistant pathogens.

Product overview

Melinta Therapeutics is a commercial-stage pharmaceutical company providing innovative therapies for acute and life-threatening illnesses. The company's portfolio consists of seven commercial-stage products: BAXDELA (delafloxacin), KIMYRSA (oritavancin), MINOCIN (minocycline) for Injection, ORBACTIV (oritavancin), REZZAYO (rezafungin for injection), TOPROL-XL (metoprolol succinate), and VABOMERE (meropenem and vaborbactam). These products focus on anti-infective treatments for acute care settings including antibiotics for skin infections, urinary tract infections, and serious hospital-acquired infections, as well as an antifungal and a cardiovascular product. The company also holds U.S. commercial rights to the investigational antibiotic cefepime-taniborbactam from Venatorx Pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Products and services

• REZZAYO (rezafungin for injection) Novel once-weekly echinocandin antifungal approved for treatment of candidemia and invasive candidiasis in adults; currently in Phase III trials for prophylaxis of invasive fungal diseases in allogeneic hematopoietic stem cell transplant patients. Marketed in the U.S. by Melinta under license from Mundipharma.
• KIMYRSA (oritavancin) Single-dose lipoglycopeptide antibiotic for treatment of acute bacterial skin and skin structure infections (ABSSSI) in adult patients.
• VABOMERE (meropenem and vaborbactam) Carbapenem antibiotic combination with beta-lactamase inhibitor for treatment of complicated urinary tract infections and carbapenem-resistant Enterobacteriaceae (CRE) infections.
• ORBACTIV (oritavancin) Lipoglycopeptide antibiotic with long half-life providing single-dose treatment of acute bacterial skin and skin structure infections (ABSSSI) in adult patients.
• MINOCIN (minocycline) for Injection Intravenous tetracycline antibiotic for treatment of serious infections caused by susceptible organisms in hospital settings.
• BAXDELA (delafloxacin) Fluoroquinolone antibiotic with broad-spectrum activity for treatment of acute bacterial skin and skin structure infections (ABSSSI).
• TOPROL-XL (metoprolol succinate) Beta-blocker cardiovascular product for treatment of hypertension, angina, and heart failure.
• Cefepime-taniborbactam Investigational beta-lactam/beta-lactamase inhibitor (BL/BLI) combination antibiotic licensed from Venatorx Pharmaceuticals in 2023 for U.S. commercialization. Under FDA review for complicated urinary tract infections (cUTI) and hospital-acquired bacterial pneumonia.

Quantifiable outcome

• 85% revenue growth achieved from 2020 to 2025 under Deerfield ownership
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• National Home Infusion Association (NHIA)minorGTM or Marketing Partner · 1 December 2024Melinta joined NHIA's Future of Infusion Advisory Council (FIAC), a strategic advisory group addressing critical issues and opportunities in the home and alternate site infusion industry.
• Venatorx PharmaceuticalscoreStrategic or Co-development Partner · 1 November 2023Exclusive license agreement for U.S. commercialization of cefepime-taniborbactam, a beta-lactam/beta-lactamase inhibitor combination antibiotic for complicated urinary tract infections and hospital-acquired bacterial pneumonia.
• BARDA (Biomedical Advanced Research and Development Authority)coreStrategic or Co-development Partner · 1 July 2023Partnership with BARDA secured initial $20.5 million in funding with potential to reach $141.9 million to advance FDA-approved antibiotic candidates through supplemental new drug applications. Also includes development of products for pediatric use and biothreat pathogens.
• EurofarmaminorChannel Partner/ Reseller/ DistributorInternational distribution partner for delafloxacin in global markets outside the U.S.
• HikmaminorChannel Partner/ Reseller/ DistributorInternational distribution partner for delafloxacin, oritavancin, meropenem and vaborbactam in their territories.
• MenariniminorChannel Partner/ Reseller/ DistributorInternational distribution partner for delafloxacin, oritavancin, meropenem and vaborbactam in Europe, Middle East, and other regions.
• XeditonminorChannel Partner/ Reseller/ DistributorInternational distribution partner for delafloxacin, oritavancin, meropenem and vaborbactam.
• MundipharmacoreStrategic or Co-development PartnerLicensing partner for rezafungin (REZZAYO) in the U.S. Melinta holds exclusive rights to commercialize rezafungin in the U.S. from Mundipharma. Joint development of Rezzayo for prophylaxis indications.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Shionogi: Global Japanese pharmaceutical company with a strong anti-infective franchise including cefiderocol (FETROJA). Comparable as a broader anti-infective portfolio player with hospital-channel focus.
• Pfizer: Diversified global pharmaceutical company with a significant hospital anti-infective portfolio. Relevant broad incumbent competitor and partner in the anti-infective therapeutics space.
• Merck & Co. Major pharmaceutical company with established hospital anti-infective products including ZERBAXA (ceftolozane/tazobactam). Comparable as a broad incumbent in the hospital anti-infective category.

Direct peers

• Tetraphase Biosciences: Developer of eravacycline (XERAVA), a fluorocycline antibiotic for complicated intra-abdominal and urinary tract infections — a direct therapeutic-area competitor within the hospital anti-infective space.
• Nabriva Therapeutics: Specialty anti-infective company commercializing lefamulin (XENLETA), a pleuromutilin antibiotic for community-acquired bacterial pneumonia. Closely aligned hospital/outpatient anti-infective commercial model.
• Scynexis: Developer of ibrexafungerp (BREXAFEMME), a novel antifungal for vulvovaginal candidiasis and invasive Candida infections. A direct peer in the hospital antifungal specialty space adjacent to REZZAYO.
• Paratek Pharmaceuticals: Specialty antibiotic company focused on tetracycline-class antibiotics (omadacycline/NUZYRA) for community-acquired and skin infections. Directly comparable as a hospital/anti-infective specialty pharma targeting resistant pathogens.
• Cidara Therapeutics: Clinical-stage anti-infective company developing antifungal and antibacterial therapies, including rezafungin-related echinocandins. Closely comparable mechanism and indication overlap with Melinta's REZZAYO franchise.

Emerging players

• Venatorx Pharmaceuticals: Clinical-stage developer of cefepime-taniborbactam, the beta-lactam/BLI combination licensed to Melinta. Comparable by therapeutic focus on resistant gram-negative infections and direct partnership overlap.

Others

• Achaogen: Former specialty antibiotics company (plazomicin/ZEMDRI) that serves as a cautionary comparable for the hospital anti-infective commercial model, given its post-launch commercial challenges and ultimate restructuring.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/melintatx
• Facebookfacebook.com/595386293860059
• LinkedInlinkedin.com/company/melinta-therapeutics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds14 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Melinta Therapeutics